

PATENT
Attorney Docket No. **CASE-02138**

Appendix 2 - Pending Claims

1. A method of monitoring immunization, comprising:
 - a) providing: i) a human, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines; and
 - d) determining if said T cells are primarily Th2 cells secreting an anti-inflammatory cytokine or primarily Th1 cells secreting an inflammatory cytokine, wherein said Th2 cells secreting an anti-inflammatory cytokine indicates that said immunizing is protective against multiple sclerosis.

25. A method of monitoring immunization, comprising:
 - a) providing: i) a human with symptoms of multiple sclerosis, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines; and
 - d) determining if said T cells are primarily Th2 cells secreting an anti-inflammatory cytokine or primarily Th1 cells secreting an inflammatory cytokine, wherein said Th2 cells secreting an anti-inflammatory cytokine indicates that said immunizing is effective for treating symptoms of multiple sclerosis.

26. A method of monitoring immunization, comprising:
 - a) providing: i) a human, and ii) an immunizing preparation comprising myelin basic protein and Incomplete Freund's Adjuvant;
 - b) immunizing said human with said immunizing preparation;
 - c) obtaining a primary cell population from said human comprising T cells capable of secreting cytokines;

PATENTAttorney Docket No. **CASE-02138**

d) adding said primary cell population to a microwell comprising a hydrophobic membrane having a first cytokine binding ligand, under conditions such that said T cell secretes a cytokine that binds to said first cytokine binding ligand;

e) adding a second cytokine binding ligand to said microwell under conditions such that said cytokine binding ligand binds to said cytokine; and

f) detecting said secreted cytokine, thereby monitoring said immunizing.

27. The method of Claim 26, wherein said detected cytokine is IL-5.

28. The method of Claim 26, wherein said detected cytokine is IL-4.

29. The method of Claim 26, wherein said detected cytokine is IL-10.

30. The method of Claim 26, wherein said detected cytokine is IFN γ .

31. The method of Claim 26, wherein said detected cytokine is IL-2.

32. The method of Claim 26, wherein said hydrophobic membrane comprises polyvinylidene difluoride.

33. The method of Claim 26, wherein said microwell comprises an enclosed bottom.

34. The method of Claim 1, wherein said determining comprises detecting said secreted cytokine.

35. The method of Claim 1, wherein said secreted cytokine is IL-5.

36. The method of Claim 1, wherein said secreted cytokine is IL-4.

37. The method of Claim 1, wherein said secreted cytokine is IL-10.

PATENT

Attorney Docket No. CASE-02138

38. The method of Claim 1, wherein said secreted cytokine is IFN γ .
39. The method of Claim 1, wherein said secreted cytokine is IL-2.
40. The method of Claim 25, wherein said determining comprises detecting said secreted cytokine.
41. The method of Claim 25, wherein said secreted cytokine is IL-5.
42. The method of Claim 25, wherein said secreted cytokine is IL-4.
43. The method of Claim 25, wherein said secreted cytokine is IL-10.
44. The method of Claim 25, wherein said secreted cytokine is IFN γ .
45. The method of Claim 25, wherein said secreted cytokine is IL-2.